D-JNKI-1

DB05660InvestigationalSmall molecule

A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of...

Mechanism: AM-111 is an inhibitor of c-Jun N-terminal kinase-mediated apoptosis and inflammation.
Curator reviewed
Primary indication: Investigated for use/treatment in hearing loss.Curator reviewed
Formula / weight: C₁₆₄H₂₈₅N₆₅O₄₁ · 3823.498 g/mol (avg)
Also known as: D-JNKI 1 peptide
Code names: AM-111 · D-JNKI-1 · XG-102 C-terminal acid

Resolves to

Compound

UNIIFU288768DPCAS1198367-70-2ChEMBLCHEMBL4297348

Structure

InChIKeyHRMVIAFZYCCHGF-BMCUWHFPSA-NSMILES

CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(O)=O)C(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(O)=O

Targets

P53779MAPK10P45984MAPK9P45983MAPK8

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with D-JNKI-1, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account